| scholarly article | Q13442814 |
| P356 | DOI | 10.1183/09031936.00069812 |
| P698 | PubMed publication ID | 23018906 |
| P50 | author | Chong-Jen Yu | Q42255080 |
| Wei-Yu Liao | Q57020031 | ||
| I-Shiow Jan | Q61140450 | ||
| P2093 | author name string | Chih-Hsin Yang | |
| Jin-Yuan Shih | |||
| Pan-Chyr Yang | |||
| Meng-Feng Tsai | |||
| Shang-Gin Wu | |||
| P433 | issue | 6 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| malignant pleural effusion | Q6743514 | ||
| P304 | page(s) | 1409-1418 | |
| P577 | publication date | 2012-09-27 | |
| P1433 | published in | European Respiratory Journal | Q12257435 |
| P1476 | title | Survival of lung adenocarcinoma patients with malignant pleural effusion | |
| P478 | volume | 41 |
| Q37592223 | ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma |
| Q34963525 | Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion |
| Q41997242 | CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation |
| Q37204010 | Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. |
| Q90352907 | Clinical course of non-small cell lung cancer patients with dry pleural dissemination: Retrospective observational study |
| Q51434808 | Current best practice in the evaluation and management of malignant pleural effusions. |
| Q64094290 | Cytology Microarray on Cell Block Preparation: A Novel Diagnostic Approach in Fluid Cytology |
| Q27300937 | Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis |
| Q48017157 | Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis |
| Q90941054 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion |
| Q36026188 | EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway |
| Q50015730 | Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy |
| Q55234466 | Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases. |
| Q42316845 | High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients |
| Q47855146 | Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors |
| Q89149871 | Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion |
| Q33897441 | Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. |
| Q30657333 | Mast cells mediate malignant pleural effusion formation. |
| Q91741802 | Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients |
| Q33716297 | Mutant KRAS promotes malignant pleural effusion formation |
| Q50130460 | Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion. |
| Q53831181 | Outcome of advanced lung cancer with central airway obstruction versus without central airway obstruction. |
| Q28830889 | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
| Q34427439 | Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib |
| Q64235237 | Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis |
| Q95840033 | Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations |
| Q37335920 | The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition |
| Q37022191 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients |
| Q90776185 | Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial |
Search more.